Please assess the completion status of the following clinical trial:

Trial Title: Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed clinically visible invasive carcinoma of the cervix, either squamous cell, adenocarcinoma or a variant of these~* Patients must be enrolled in NCIC CXC.1 (phase 3 study assessing the addition of tirapazamine) and randomized to the tirapazamine arm~* No known bleeding disorder~* Willing to undergo a clinical exam to obtain tissue biopsy for hypoxia marker analysis and DNA damage assessments~Exclusion Criteria:~* Inability to give informed consent~* Criteria below for contrast MRI only :~  1. Chronic renal disease currently on dialysis~ 2. Renal insufficiency defined as a Glomerular Filtration Rate (GFR) ≤15cc/min , serum Cr \>130, or a BUN\>7 measured~ 3. Current pacemaker, tens neuro-stimulator, implanted drug infusion devices, any metal implants, foreign metals objects in eyes, aneurysm clips

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).